Preserved animals and organisms

Fenofibrate, a drug in the fibrate class, can be used in the in the treatment of hypertriglyceridemia or hypercholesterolemia. Ungraded products supplied by Spectrum are indicative of a grade suitable for general industrial use or research purposes

General description Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Fenofibrate

General description This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the

A hypolipidemic PPARα agonist.Fenofibrate has been used:• to study its effect on plasma lipids, liver phenotype and gene expression；• to study its impact on endothelium-dependent vasodilatation of thoracic aorta；• to administer to NASH knock-in mice

A hypolipidemic PPARα agonist.Fenofibrate has been used:• to study its effect on plasma lipids, liver phenotype and gene expression；• to study its impact on endothelium-dependent vasodilatation of thoracic aorta；• to administer to NASH knock-in mice

A hypolipidemic PPARα agonist.Fenofibrate has been used:• to study its effect on plasma lipids, liver phenotype and gene expression；• to study its impact on endothelium-dependent vasodilatation of thoracic aorta；• to administer to NASH knock-in mice

A hypolipidemic PPARα agonist.Fenofibrate has been used:• to study its effect on plasma lipids, liver phenotype and gene expression；• to study its impact on endothelium-dependent vasodilatation of thoracic aorta；• to administer to NASH knock-in mice

A hypolipidemic PPARα agonist.Fenofibrate has been used:• to study its effect on plasma lipids, liver phenotype and gene expression；• to study its impact on endothelium-dependent vasodilatation of thoracic aorta；• to administer to NASH knock-in mice

A hypolipidemic PPARα agonist.Fenofibrate has been used:• to study its effect on plasma lipids, liver phenotype and gene expression；• to study its impact on endothelium-dependent vasodilatation of thoracic aorta；• to administer to NASH knock-in mice